TY - JOUR
T1 - Prognostic value of CD163+ macrophages in solid tumor malignancies
T2 - A scoping review.
AU - Mathiesen, Henriette
AU - Juul-Madsen, Kristian
AU - Tramm, Trine
AU - Vorup-Jensen, Thomas
AU - Møller, Holger Jon
AU - Etzerodt, Anders
AU - Andersen, Morten Nørgaard
N1 - Copyright © 2025. Published by Elsevier B.V.
PY - 2025/4
Y1 - 2025/4
N2 - Tumor-associated macrophages (TAMs) play crucial roles in development and progression of malignant diseases. Notably, CD163
+ TAMs likely perform specific pro-tumorigenic functions, suggesting that this subset may serve as both prognostic biomarkers and targets for future anti-cancer therapy. We conducted a scoping review to map the current knowledge on the prognostic role of CD163
+ TAMs in the five most lethal cancers worldwide: Lung, colorectal, gastric, liver, and breast cancer. For all cancer types, most studies showed that high tumoral presence of CD163
+ cells was associated with poor patient outcome, and this association was more frequently observed when CD163
+ cells were measured at the tumor periphery compared to more central parts of the tumor. These results support that CD163
+ TAMs represent a biomarker of poor patient outcome across a variety of solid tumors, and highlight the relevance of further investigations of CD163
+ TAMs as targets of future immunotherapies.
AB - Tumor-associated macrophages (TAMs) play crucial roles in development and progression of malignant diseases. Notably, CD163
+ TAMs likely perform specific pro-tumorigenic functions, suggesting that this subset may serve as both prognostic biomarkers and targets for future anti-cancer therapy. We conducted a scoping review to map the current knowledge on the prognostic role of CD163
+ TAMs in the five most lethal cancers worldwide: Lung, colorectal, gastric, liver, and breast cancer. For all cancer types, most studies showed that high tumoral presence of CD163
+ cells was associated with poor patient outcome, and this association was more frequently observed when CD163
+ cells were measured at the tumor periphery compared to more central parts of the tumor. These results support that CD163
+ TAMs represent a biomarker of poor patient outcome across a variety of solid tumors, and highlight the relevance of further investigations of CD163
+ TAMs as targets of future immunotherapies.
KW - CD163
KW - Cancer
KW - Patient prognosis
KW - Solid tumor malignancy
KW - Targeted immunotherapy
KW - Tumor-associated macrophage
UR - http://www.scopus.com/inward/record.url?scp=85216020739&partnerID=8YFLogxK
U2 - 10.1016/j.imlet.2025.106970
DO - 10.1016/j.imlet.2025.106970
M3 - Review
C2 - 39778658
SN - 0165-2478
VL - 272
SP - 106970
JO - Immunology Letters
JF - Immunology Letters
M1 - 106970
ER -